Pharmacogenetics of antihypertensive drug responses

American Journal of PharmacoGenomics

Volumn 4, Issue 3, 2004, Pages 151-160

  Schwartz, Gary L ^a   Turner, Stephen T ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADDUCIN; ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADDUCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CATECHOL METHYLTRANSFERASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOSINOPRIL; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IMIDAPRIL; IRBESARTAN; LISINOPRIL; METOPROLOL; MINOXIDIL; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; DRUG METABOLISM; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME; GENOTYPE; HAPLOTYPE; HUMAN; HYPERTENSION; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; GENE FREQUENCY; GENOME; HUMANS; HYPERTENSION; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 3042710748     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200404030-00002     Document Type: Review

References (85)

1. Hajjar I, Kotchen TA. Trends in the prevalence, awareness, treatment and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206
2. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275 (20): 1571-6
3. Whelton PK, He J, Perneger TV, et al. Kidney damage in 'benign' essential hypertension. Curr Opin Nephrol Hypertens 1997; 6 (2): 177-83
4. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347 (9009): 1141-5
5. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358 (9290): 1305-15
6. Turner ST, Schwartz GL, Chapman AB, et al. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens 2001; 19: 1-11
7. Chapman AB, Schwartz GL, Boerwinkle E, et al. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide in African-American an Caucasians with essential hypertension. Kidney Int 2002; 1 (3): 1047-55
8. Guyton A, Hall J, Lohmeier T, et al. Blood pressure regulation: basic concepts. Fed Proc 1981; 40: 2252-6
9. Motulsky A. Drug reactions, enzymes and biochemical genetics. JAMA 1957; 165: 835-7
10. Vogel F. Moderne prblems der humangenetik. Ergeb Inn Med Kinderheilk 1959; 12: 52-125
11. Kaplan N. Treatment of hypertension: drug therapy. In: Kaplan N, editor. Clinical hypertension. Baltimore (MD): Williams & Wilkins, 1998: 181-264
12. Israili Z. Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man. Annu Rev Pharmacol Toxicol 1979; 19: 25-52
13. Von Bahr C, Collste P, Frisk-Holmberg M, et al. Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension. Clin Pharmacol Ther 1976; 20: 130-7
14. Beermann B, Groschinsky-Grind M. Antihypertensive effect of various doses of hydrochlorothiazide and it relation to the plasma level of the drug. Eur J Clin Pharmacol 1978; 13: 195-201
15. Materson B, Reda D, Cushman W, et al. Single-drug therapy for hypertension in men: a comparision of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-21
16. Materson B, Reda C, Cushman W. Department of Veterans Affairs single drug therapy of hypertension study: revised figures and new data. Am J Hypertens 1995; 8: 189-92
17. Materson B, Reda D, Preston R, et al. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Arch Intern Med 1995; 155: 1757-62
18. Hall W, Reed J, Flack J, et al. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks. Arch Intern Med 1998; 158 (18): 2029-34
19. Zusman R. Are there differences among angiotensin receptor blockers? Am J Hypertens 1999; 12: 231S-5S
20. Burnier M, Brunner H. Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol 1999; 10: S278-82
21. Wahl J, Turlapaty P, Bramah N, et al. Comparison of acebutolol and propranolol in essential hypertension. Am Heart J 1985; 109: 313-21
22. Leonetti G, Cuspidi C. Choosing the right ACE inhibitor: a guide to selection. Drugs 1995; 49: 516-35
23. Fletcher A, Franks P, Bulpitt C. The effect of withdrawing antihypertensive therapy: a review. J Hypertens 1988; 6: 431-6
24. Ekbom T, Lindholm L, Oden A, et al. A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people. J Intern Med 1994; 235: 581-8
25. Kalow W. Pharmacogenetics: its biologic roots and the medical challenge. Clin Pharmacol Ther 1993; 54: 235-41
26. Murphy E. One cause? Many causes? The argument from the bimodal distribution. J Chronic Dis 1964; 17: 301-24
27. Shah R, Oates N, Idle J, et al. Beta-blockers and drug oxidation status. Lancet 1982; 1: 508-9
28. Dayer P, Balant L, Kupfer A, et al. Conbtribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoreceptor blocking agents. Eur J Clin Pharmacol 1983; 24: 797-9
29. Shepherd A, McNay J, Ludden T, et al. Plasma concentration and acetylator phenotype determine response to oral hydralazine. Hypertension 1981; 3: 580-5
30. Spielsberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Parmacokinet Biopharm 1996; 24: 509-19
31. Campbell N, Dunnette J, Mwaluko G, et al. Platelet phenol sulfotransferase and erythrocyte catechol-O-methyltransferase activities: correlation with methyldopa metabolism. Clin Pharmacol Ther 1984; 35: 55-63
32. Anderson RJ, Kudlacek PE, Clemens DL. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact 1998; 109: 53-67
33. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Hum Genet 2001; 2: 9-39
34. Hallberg P, Karlsson J, Kurland L, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002; 20: 2089-93
35. Sakeda T, Nakamura T, Okumura K. Pharmacokinetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003; 4 (4): 397-410
36. Bianchi G, Swales J. Do we need more anti-hypertensive drugs: lessons from the new biology. Lancet 1995; 345: 1555-7
37. Ferari P. Pharmacogenomics: a new approach to individual therapy of hypertension? Curr Opin Nephrol Hypertens 1998; 7: 217-22
38. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353-7
39. Glorioso N, Manunta P, Filigheddu F, et al. The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999; 34 (4 Pt 1): 649-54
40. Sciarrone MT, Stella P, Barlassina C, et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003 Mar; 41 (3): 398-403
41. Turner ST, Chapman AB, Schwartz GL, et al. Effects of endothelial nitric oxide synthase, α-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003; 16: 834-9
42. Hingorani AD, Jia H, Stevens PA, et al. Renin-angiotensin system gene polymorphisms influence blood pressure and response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13 (12 Pt 2): 1602-9
43. Liljedahl U, Karlsson J, Melhus H, et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 2003 Jan; 13 (1): 7-17
44. Dudley C, Keavney B, Casadei B, et al. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996; 14 (2): 259-62
45. Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2)-344 C/T polymorphism is related to antihypertensive response: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA) Trial. Am J Hypertens 2002; 15: 389-93
46. Kurland L, Liljedahl U, Karlsson J, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004 Jan; 17 (1): 8-13
47. Frazier L, Turner ST, Schwartz GL, et al. Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenet J 2004; 4: 17-23
48. Li X, Du Y, Huang X. Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol Ther 2003; 8 (1): 25-30
49. Stavroulakis GA, Makris TK, Krespi PG, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14 (4): 427-32
50. Ohmichi N, Iwai N, Uchida Y, et al. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997; 10: 951-5
51. Kurland L, Melhus H, Karlson J, et al., on behalf of the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19: 1783-7
52. Schwartz GL, Turner ST, Chapman AB, et al. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002; 62: 1718-23
53. Sasaki M, Oki T, Luchi A, et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed doppler echocardiographic studies. J Hypertens 1996; 14 (12): 1403-8
54. Moriyama T, Kitamura H, Ochi S, et al. Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 1995; 6: 1674-8
55. Nakano Y, Oshima T, Watanabe M, et al. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. Am J Hypertens 1997; 10: 1064-8
56. Benetos A, Cambien F, Gautier S, et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28: 1081-4
57. Ortlepp JR, Hanrath P, Mevissen V, et al. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002; 445: 151-2
58. s alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999; 34 (1): 8-14
59. Turner ST, Schwartz GL, Chapman AB, et al. C825T polymorphism of the G protein beta (3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37: 739-43
60. Nürnberger J, Dammer S, Mitchell A, et al. Effect of the C825T polymorphism of the G protein β3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. Clin Pharmacol Ther 2003; 74: 53-60
61. 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74: 44-52
62. O'Shaughnessy KM, Fu B, Dickerson C, et al. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure of heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 2000; 99 (3): 233-8
63. 2-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians. J Hypertens 2000 Jun; 18 (6): 687-93
64. Manunta P, Burnier M, D'Amico M, et al. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. Hypertension 1999; 33: 694-7
65. Grant FD, Romero JR, Jeunemaitre X, et al. Low-renin hypertension, altered sodium homeostasis, and an α-adducin polymorphism. Hypertension 2002; 39: 191-6
66. Schunkert H, Hense HW, Doring A, et al. Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 1998; 32: 510-3
67. Siffert W, Rosskopf D, Moritz A, et al. Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. J Clin Invest 1995; 96: 759-66
68. Virchow S, Ansorge N, Rübben H, et al. Enhanced fMLP-stimulated chemotaxis in human neutrophils from individuals carrying the G protein beta3 subunit 825 T-allele. FEBS Lett 1998; 436: 155-8
69. 1-adrenergic receptor. Biol Chem 1999; 274: 12670-4
70. 1-adrenergic receptor affect agnoist-promoted trafficking. J Cardiovasc Pharmacol 2002; 39: 155-60
71. 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 2002; 277 (34): 30429-35
72. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71: 169-80
73. Rigat B, Hubert C, Alhenic-Gelas F, et al. An insertion/deletion polymorphism in the angitoensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6
74. Macmahon S. Blood pressure and the risk of cardiovascular disease. N Engl J Med 2000; 342: 50-2
75. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 590-615
76. Brass LW, Alberts MJ. Genetic epidemiology and family studies of stroke. In: Alberts MJ, editor. Genetics of cerebrovascular disease. Armonk (NY): Futura, 1999: 159-82
77. Peyser PA. Genetic epidemiology of coronary artery disease. Epidemiol Rev 1997; 19: 80-90
78. Fredman BI, Satko SG. Genes and renal disease. Curr Opin Nephrol Hypertens 2000; 9: 273-7
79. Psaty BM, Smith NL, Heckert SR, et al. Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction and stroke in persons with treated hypertension. JAMA 2002; 287: 1680-9
80. Vincent M, Samani NJ, Gauguier D, et al. A pharmacogenetic approach to blood pressure in Lyon hypertensive rats: a chromosome 2 locus influences the response to a calcium antagonist. J Clin Invest 1997; 100: 2000-6
81. Kruglyak L. The use of a genetic map of biallelic markers in linkage studies. Nat Genet 1997; 17: 21-4
82. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409: 928-33
83. Olivier M. A haplotype map of the human genome. Physiol Genomics 2003; 13: 3-9
84. Nelson MR, Kardia SL, Ferrell RE, et al. A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation. Genome Res 2001; 11: 458-70
85. Sing CF, Stengard JH, Kardia SLR. Genes, environment, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23 (7): 1190-6